Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:1377:13-26.
doi: 10.1007/978-981-19-1592-5_2.

HDL and Cholesterol Ester Transfer Protein (CETP)

Siying Deng  1 , Jiewen Liu  2 , Chenguang Niu  3
Affiliations

HDL and Cholesterol Ester Transfer Protein (CETP)

Siying Deng et al. Adv Exp Med Biol. 2022.

Abstract

Cholesterol ester transfer protein (CETP) is important clinically and is one of the major targets in cardiovascular disease studies. With high conformational flexibility, its tunnel structure allows unforced movement of high-density lipoproteins (HDLs), VLDLs, and LDLs. Research in reverse cholesterol transports (RCT) reveals that the regulation of CETP activity can change the concentration of cholesteryl esters (CE) in HDLs, VLDLs, and LDLs. These molecular insights demonstrate the mechanisms of CETP activities and manifest the correlation between CETP and HDL. However, animal and cell experiments focused on CETP give controversial results. Inhibiting CETP is found to be beneficial to anti-atherosclerosis in terms of increasing plasma HDL-C, while it is also claimed that CETP weakens atherosclerosis formation by promoting RCT. Currently, the CETP-related drugs are still immature. Research on CETP inhibitors is targeted at improving efficacy and minimizing adverse reactions. As for CETP agonists, research has proved that they also can be used to resist atherosclerosis.

Keywords: Anti-atherosclerosis; CETP agonists; CETP inhibitor; Cholesterol ester transfer protein; Reverse cholesterol transport.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shrestha S, Wu BJ, Guiney L, Barter PJ, Rye K-A (2018) Cholesteryl ester transfer protein and its inhibitors. J Lipid Res 59:772–783. https://doi.org/10.1194/jlr.R082735 - DOI - PubMed - PMC
    1. Gordon D et al (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8–15. https://doi.org/10.1161/01.cir.79.1.8 - DOI - PubMed
    1. Barter P et al (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357:1301–1310. https://doi.org/10.1056/NEJMoa064278 - DOI - PubMed
    1. Boekholdt SM et al (2013) Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation 128:1504–1512. https://doi.org/10.1161/circulationaha.113.002670 - DOI - PubMed
    1. de la Llera-Moya M et al (2010) The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 30:796–801. https://doi.org/10.1161/ATVBAHA.109.199158 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources